Pinnacle Advisory Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pinnacle Advisory Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,940	Closed	-$377K	–	170
2019 Q3	$377K	Sell	4,940 -13,563	-73%	-$1.13M	0.03%	126
2019 Q2	$1.62M	Buy	18,503 +2,120	+13%	+$181K	0.11%	64
2019 Q1	$1.48M	Buy	16,383 +670	+4%	+$57K	0.1%	64
2018 Q4	$1.13M	Sell	15,713 -10,800	-41%	-$870K	0.08%	72
2018 Q3	$2.54M	Sell	26,513 -11,271	-30%	-$1.09M	0.18%	41
2018 Q2	$3.6M	Buy	37,784 +25,336	+204%	+$2.33M	0.22%	35
2018 Q1	$1.09M	Buy	12,448 +4,643	+59%	+$424K	0.06%	77
2017 Q4	$662K	Buy	7,805 +415	+6%	+$34.8K	0.04%	113
2017 Q3	$640K	Buy	7,390 +620	+9%	+$49.7K	0.04%	105
2017 Q2	$523K	Buy	6,770 +815	+14%	+$57.8K	0.03%	112
2017 Q1	$413K	Buy	5,955 +1,870	+46%	+$126K	0.03%	128
2016 Q4	$242K	Buy	+4,085	New	+$252K	0.02%	168

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Pinnacle Advisory Group's XBI Position: Q4 2019 in Review

Pinnacle Advisory Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2019, closing a stake of 4,940 shares — an estimated $377K sold.

Pinnacle Advisory Group first reported a position in XBI in Q4 2016 and held it in 12 quarters. The position peaked at $3.6M in Q2 2018. 474 funds tracked by Wall St. Rank hold XBI as of Q4 2019.

Pinnacle Advisory Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2019 after selling out during the quarter.
Pinnacle Advisory Group sold 4,940 State Street SPDR S&P Biotech ETF shares in Q4 2019, an estimated $377K.
Pinnacle Advisory Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 12 quarters.
Pinnacle Advisory Group's State Street SPDR S&P Biotech ETF position peaked at $3.6M in Q2 2018.
474 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2019.

Based on Pinnacle Advisory Group's 13F filing for Q4 2019, filed 5 Feb 2020.